Pemvidutide clinical trials
How each study uses pemvidutide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pemvidutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Pemvidutide
- 5
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Who runs them
Industry 5 · Other 0
Altimmune, Inc. (5)
Often tested with
Tested in the same studies.
Atorvastatin (1) · Ethinyl Estradiol (1) · Levonorgestrel (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pemvidutide.
- Sep 2027RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Phase 2 · Altimmune, Inc.
Studies
Open first, then newest update. How each study uses pemvidutide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHRecruitingPhase 3Altimmune, Inc.NCT07795164Written as Pemvidutide
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Active, not recruitingPhase 2Altimmune, Inc.NCT07009860Written as Pemvidutide
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightCompletedPhase 2Altimmune, Inc.NCT06987513Written as Pemvidutide
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Altimmune, Inc.NCT05989711Written as Pemvidutide
- Pemvidutide (ALT-801) DDI Study in Healthy VolunteersCompletedPhase 1Altimmune, Inc.NCT04972396Written as Pemvidutide
Codes
What other systems call pemvidutide · ClinicalTrials.gg INT015953
- UNII (FDA) A35F525WBGPEMVIDUTIDEOne source FDA
- NCI Thesaurus C188549PemvidutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A35F525WBG | PEMVIDUTIDE | One source FDA |
| NCI Thesaurus | C188549 | Pemvidutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.